about
Omics databases on kidney disease: where they can be found and how to benefit from themRenal urinary shear stress: a novel actor in nephropathiesThe KUPKB: a novel Web application to access multiomics data on kidney diseaseProteasix: a tool for automated and large-scale prediction of proteases involved in naturally occurring peptide generationEvaluation of the Zucker diabetic fatty (ZDF) rat as a model for human disease based on urinary peptidomic profilesLong term metabolic syndrome induced by a high fat high fructose diet leads to minimal renal injury in C57BL/6 miceComparative Analysis of Label-Free and 8-Plex iTRAQ Approach for Quantitative Tissue Proteomic AnalysisThe Proteasix OntologySystems biology combining human- and animal-data miRNA and mRNA data identifies new targets in ureteropelvic junction obstructionAssessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney diseaseProteomics of vitreous humor of patients with exudative age-related macular degenerationDual effect of chemokine CCL7/MCP-3 in the development of renal tubulointerstitial fibrosis.Identification of urinary peptide biomarkers associated with rheumatoid arthritis.Populous: a tool for building OWL ontologies from templates.Label-free quantitative urinary proteomics identifies the arginase pathway as a new player in congenital obstructive nephropathy.The KUPNetViz: a biological network viewer for multiple -omics datasets in kidney diseases.Kinin B1 receptor antagonism is equally efficient as angiotensin receptor 1 antagonism in reducing renal fibrosis in experimental obstructive nephropathy, but is not additive.Blockade of the kinin B1 receptor ameloriates glomerulonephritisIdentification of Symptomatic Fetuses Infected with Cytomegalovirus Using Amniotic Fluid Peptide BiomarkersIdentification of ageing-associated naturally occurring peptides in human urineLysophosphatidic acid and renal fibrosis.A capillary electrophoresis coupled to mass spectrometry pipeline for long term comparable assessment of the urinary metabolome.Congenital ureteropelvic junction obstruction: human disease and animal models.Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application.Renal fibrosis: insight from proteomics in animal models and human disease.Lysophosphatidic acid-1-receptor targeting agents for fibrosis.Clinical proteomics in obstetrics and neonatology.Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases.miRNAs in urine: a mirror image of kidney disease?The application of multi-omics and systems biology to identify therapeutic targets in chronic kidney disease.The role of urinary peptidomics in kidney disease research.Unveiling antimicrobial peptide-generating human proteases using PROTEASIX.New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis.Renal tubular fluid shear stress facilitates monocyte activation toward inflammatory macrophages.Comparison of higher energy collisional dissociation and collision-induced dissociation MS/MS sequencing methods for identification of naturally occurring peptides in human urine.Toward the definition of a peptidome signature and protease profile in chronic periodontitis.Discovery and validation of urinary biomarkers for detection of renal cell carcinoma.Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy.LPA1 receptor activation promotes renal interstitial fibrosis.Urinary peptidomics analysis reveals proteases involved in diabetic nephropathy.
P50
Q24658628-6A5A4853-4943-4C3A-B4B8-C0A9615BEFA5Q26865487-27FCAA87-FED4-446C-ADC4-A7D1ED6356CAQ28260266-C4B00B3F-6DDF-4A46-A826-D50B1781AE88Q28284158-49EC4A30-5EEA-4F17-8A58-31CA2D306247Q28484239-D507EB61-CAAB-4B8F-9D98-0452E9BE7A12Q28534010-FD0BF515-62B8-4C8A-ABCF-6164AC71C375Q28547700-A57F9FBD-39FF-4446-8297-61A3076CB1DDQ28829147-1693A449-BB79-45B1-8B29-D90B6ED945AFQ30253062-EB656CDF-14DB-4FF0-A7F5-55EB0F9E8498Q33591146-63E498B2-9825-4A3F-A3C2-21AA56113263Q33591146-ED124013-C4F0-4353-B5CB-E3E0ADBC24F4Q33610106-8F6C49D2-6E5E-4677-A043-689C4A4AE317Q33704805-D6458615-8200-4269-B08E-B57B2F608687Q34075303-B47BCBC9-11AD-4ABA-84B6-FBC52BEA341BQ34177117-1D3C25FE-CE2D-47D2-A040-33F6C7D875C5Q34634938-0AC4AF8E-CB4C-47A6-BB0F-70309022CBC2Q34862908-77153BB3-447B-4014-809C-BE43F62C8F4EQ35037194-16ED2912-889F-4A88-BA84-8648A7F91A12Q35153206-E1B2118E-CD56-462D-81C8-C84FA74010DDQ35903895-E314DA74-556F-412E-BD63-41BFDE224EB2Q36544030-1F6F4020-6719-4462-9D54-337430B4B038Q36960382-619B7030-514E-4B91-8067-58D6FEB31435Q37303421-2F1AC82C-6516-4CCB-A68A-DC0A724BDE25Q37777427-D6BB7842-8B8A-47B2-890E-5F8912562DFAQ37806433-8014BF01-B472-4A4A-9B17-6E862D53017CQ37828116-45B823C0-D2EC-44BC-BA26-3C7B9034C87CQ37857284-CC84C736-261A-424A-81B8-1091D9755DE3Q38176934-3163F3E2-B9C9-45D7-A643-4D602E565DA7Q38222628-D01D758D-E178-417D-9067-C074FA08CA57Q38347455-B5D00E29-10A5-49C0-8357-7FD3BCC14A74Q38612850-5190F8C7-91E2-43F6-9DF8-52D567FE940CQ38735013-20420998-E9DA-4AE3-99D8-9AB03C81D332Q38932387-5D9000F9-23DD-4F8C-B634-ADCDB26C6A4DQ38986294-58933DD0-52EC-49EF-AFC4-5BBEFD788ECCQ39379434-47934F97-81FD-49D3-AD8E-9C4A44FFDCABQ41142978-D27EDFAB-8F3F-4574-A036-CF334C39F9EAQ41452333-D19EB208-1E76-423A-9C8A-2D7B3C7E82CCQ44638298-274DCE06-15E4-4C25-86D6-4528DB90BC7AQ46352491-FA82EBBE-3CE7-479E-B0CE-CEE419FB43BFQ46899860-6A3B7019-648E-47F3-946C-220EDE465BA9
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Julie Klein
@ast
Julie Klein
@en
Julie Klein
@es
Julie Klein
@sl
جولي كلاين
@ar
type
label
Julie Klein
@ast
Julie Klein
@en
Julie Klein
@es
Julie Klein
@sl
جولي كلاين
@ar
prefLabel
Julie Klein
@ast
Julie Klein
@en
Julie Klein
@es
Julie Klein
@sl
جولي كلاين
@ar
P214
P1053
M-7088-2017
P106
P21
P214
P2456
P31
P3829
P496
0000-0002-3279-0559
P734
P735
P7859
viaf-212175936